RAPT Therapeutics to Participate in Several Upcoming Investor Conferences

Rhea-AI Summary

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2022 – RAPT Therapeutics (Nasdaq: RAPT) announced participation in three upcoming investor conferences in November. The conferences include the Guggenheim 4th Annual Immunology and Neurology Day on November 15, the Piper Sandler 33rd Annual Healthcare Conference on November 29, and the Evercore ISI 5th Annual Virtual HealthCONx Conference on November 30. Interested parties can access live webcasts and recordings through the RAPT Therapeutics website.

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that members of the RAPT management team will participate in the following investor conferences in November.

• Guggenheim 4^th Annual Immunology and Neurology Day - Tuesday, November 15, 2022, at 2:10 p.m. ET in New York, NY
  

• Piper Sandler 33^rd Annual Healthcare Conference - Tuesday, November 29, 2022, at 8:00 a.m. ET in New York, NY
  

• Evercore ISI 5^th Annual Virtual HealthCONx Conference - Wednesday, November 30, 2022, at 3:55 p.m. ET
  

To access the live webcasts or subsequent archived recordings of the company presentations, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.

About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, RPT193 and FLX475, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.

RAPT Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com

RAPT Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com

FAQ

What are the investor conferences RAPT Therapeutics is attending in November 2022?

RAPT Therapeutics will participate in the Guggenheim 4th Annual Immunology and Neurology Day on November 15, the Piper Sandler 33rd Annual Healthcare Conference on November 29, and the Evercore ISI 5th Annual Virtual HealthCONx Conference on November 30.

Where can I find the webcasts for RAPT Therapeutics' investor presentations?

Webcasts and archived recordings of RAPT Therapeutics' presentations can be accessed on their official website.

What is RAPT Therapeutics focused on?

RAPT Therapeutics is a biopharmaceutical company focused on developing oral small molecule therapies for inflammatory diseases and oncology.

What kind of drug candidates is RAPT developing?

RAPT is developing two unique drug candidates, RPT193 and FLX475, targeting CCR4 for inflammation and cancer respectively.